A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- Drug: ZIO-201
- Registration Number
- NCT00421135
- Lead Sponsor
- Alaunos Therapeutics
- Brief Summary
The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Metastatic and /or unresectable disease state after previous standard chemotherapy
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single Arm ZIO-201 ZIO-201
- Primary Outcome Measures
Name Time Method toxicities 6 months
- Secondary Outcome Measures
Name Time Method pharmacokinetics 6 months